來(lái)自意大利米蘭大學(xué),，Maples大學(xué)的一個(gè)研究團(tuán)隊(duì)在最新的Science上發(fā)表文章，A Gene Network Regulating Lysosomal Biogenesis and Function,，發(fā)現(xiàn)了一個(gè)調(diào)節(jié)溶酶體功能的基因網(wǎng)絡(luò),。
眾所周知，溶酶體（lysosome）為細(xì)胞漿內(nèi)由單層脂蛋白膜包繞的內(nèi)含一系列酸性水解酶的小體,。是細(xì)胞內(nèi)具有單層膜囊狀結(jié)構(gòu)的細(xì)胞器,，溶酶體內(nèi)含有許多種水解酶類，能夠分解很多種物質(zhì),，溶酶體被比喻為細(xì)胞內(nèi)的“酶?jìng)}庫(kù)”“消化系統(tǒng)” “細(xì)胞垃圾處理站”,。
溶酶體可以將有害的分子進(jìn)行分解，包括那些在阿茲海默癥,、亨廷頓氏病和帕金森氏病以及許多所謂的“溶酶體貯積癥”患者的細(xì)胞中所積聚的有害分子,。
Marco Sardiello等人發(fā)現(xiàn)，溶酶體細(xì)胞器的合成以及功能的執(zhí)行受一個(gè)基因網(wǎng)路的調(diào)控,，這些基因間的協(xié)調(diào)表達(dá)受轉(zhuǎn)錄因子TFEB控制,。TFEB本身可以在溶酶體功能障礙的時(shí)候被激活。它可調(diào)節(jié)細(xì)胞中溶酶體的豐富程度以及其降解復(fù)雜分子的能力,。
Marco Sardiello研究小組以大鼠細(xì)胞為模型驗(yàn)證他們的理論,。結(jié)果發(fā)現(xiàn)，增加TFEB的活性可幫助溶酶體降解引起亨廷頓氏病的蛋白,。
這些研究成果可能為阿茲海默癥,、亨廷頓氏病和帕金森氏病的治療帶來(lái)新的思路。（生物谷Bioon.com）
生物谷推薦原始出處：
Science June 25, 2009 DOI: 10.1126/science.1174447
A Gene Network Regulating Lysosomal Biogenesis and Function
Marco Sardiello 1, Michela Palmieri 1, Alberto di Ronza 1, Diego Luis Medina 1, Marta Valenza 2, Vincenzo Alessandro Gennarino 1, Chiara Di Malta 1, Francesca Donaudy 1, Valerio Embrione 1, Roman S. Polishchuk 3, Sandro Banfi 1, Giancarlo Parenti 4, Elena Cattaneo 2, Andrea Ballabio 4*
1 Telethon Institute of Genetics and Medicine (TIGEM), Via P. Castellino 111, 80131 Naples, Italy.
2 Department of Pharmacological Sciences and Center for Stem Cell Research, University. of Milan, Via Balzaretti 9, 20133 Milan, Italy.
3 Telethon Electron Microscopy Core Facility, Department of Cell Biology and Oncology, Consorzio Mario Negri Sud, I-66030 Santa Maria Imbaro, Chieti, Italy.
4 Telethon Institute of Genetics and Medicine (TIGEM), Via P. Castellino 111, 80131 Naples, Italy.; Department of Pediatrics, Federico II University, Via S. Pansini 5, 80131 Naples, Italy.
Lysosomes are organelles central to degradation and recycling processes in animal cells. Whether lysosomal activity is coordinated to respond to cellular needs remains unclear. We found that most lysosomal genes exhibit coordinated transcriptional behavior and are regulated by the transcription factor TFEB. Under aberrant lysosomal storage conditions, TFEB translocated from the cytoplasm to the nucleus, resulting in the activation of its target genes. TFEB overexpression in cultured cells induced lysosomal biogenesis and increased the degradation of complex molecules, such as glycosaminoglycans (GAGs) and the pathogenic protein causing Huntington disease. Thus, a genetic program controls lysosomal biogenesis and function, providing a potential therapeutic target to enhance cellular clearing in lysosomal storage disorders and neurodegenerative diseases.
